Sharechat Logo

Oceania Healthcare Limited (NZX: OCA) DRP Strike Price for 2021 Interim Dividend

Tuesday 16th February 2021

Text too small?

Oceania Healthcare Limited advises that the strike price for the Dividend Reinvestment Plan (DRP) operating in respect of the dividend payable on 24 February 2021 has been set at NZ$1.5331 per share.

This strike price will apply in calculating the number of shares to be issued to participants who have elected to receive additional shares rather than cash.

The strike price has been determined, in accordance with the DRP, as the volume weighted average sale price in New Zealand dollars for Oceania Healthcare shares, calculated on all trades of Oceania Healthcare shares which took place through the NZX Main Board over the period of five trading days starting on 9 February 2021, less a 2.5% discount.

Shareholders who have elected to participate in the DRP will receive shares instead of cash in respect of the dividend payable on 24 February 2021.

The new shares will rank pari passu with existing shares on issue as at the date of their issue.

Please see the link below for details:

DRP Strike Price for 2021 Interim Dividend

Source: Oceania Healthcare Limited



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Meridian Energy monthly operating report for July 2022
Cannasouth to launch a pro-rata renounceable rights issue
August 12th Morning Report
2022 Annual Shareholders' Meeting & Director Nominations
Rakon 2022 Annual Meeting Chair's Address and Presentation
VHP - Full year results release
RAKON FY23 Earnings Guidance
August 11th Morning Report
Deferral of FDA consideration of enforcement discretion
MHJ - Response to ASX Query